125 results about "Colitic cancer" patented technology

The present application discloses an epigenetic marker for colon cancer.

This invention relates to NPC-1 antigen on the MUC5AC protein and 16C3 antigen on CEACAM5 and CEACAM6 proteins, and 31.1 epitope on the A33 protein are differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages. Further, NPC-1, 16C3, and/or 31.1 epitope specific antibodies and diagnostic and therapeutic methods of use.

Prodrug compounds which metabolize into 5-ASA or analogs thereof, and taurine or analogs thereof, in the colon site are disclosed. Pharmaceutical compositions including the compounds, and methods of treatment using the compounds, are also disclosed. Such compounds have utility for treating or preventing gastrointestinal disorders, including colon cancer, ulcerative colitis and Crohn's disease.

Various molecules associated with disorders such as colon cancer are disclosed. The invention also discloses diagnostic and therapeutic methods based upon these molecules.

The invention provides compositions and methods for useful for the diagnosis of inflammatory bowel disease, ETBF-induced colitis, colonic hyperplasia and/or colon carcinogenesis in a subject in biological samples (e.g., stool, urine, blood, serum, tissue). The invention further provides compositions and methods for the treatment or prevention of colitis, colon cancer, or inflammatory bowel disease (e.g., Crohn's disease).

Compounds of Formula Ia and Ic having a lactone structure and an methylene group at the alpha-position of the lactone structure and methods for using and making the compounds have been disclosed. The lactone compounds can be reacted with an neucleaphilic agent to open the lactone ring to a compound of Formula Ib. The lactone of Formula Ia and its functional derivatives have been isolated from Securidaca virgata. These compounds are referred to as LMSV-6 or Securolide™. The purified compounds have demonstrated activity in assays for anti-bacterial and anti-fungal activities, and for treating proliferation disorders such as cancer. Based on the in vitro assays, the lactones are useful for treating proliferation disorders including, for example, breast cancer, colon cancer, rectal cancer, stomach cancer, pancreatic cancer, lung cancer, liver cancer, ovarian cancer, esophageal cancer, and leukemia. They are also effective for treatment of bacterial and fungal infections, including treatment of peptic ulcer disease, gingivitis and periodontitis. The lactone and its derivatives has the following chemical structure:

wherein R₁-R₉ and Y₁-Y₃ taken independently are preferably a hydrogen atom, a halogen atom, a hydroxyl group, or any other organic groups or groupings which optionally include a heteroatom such as oxygen, sulfur, or nitrogen groupings in linear, branched, or cyclic structural formats; Z and X are independently and preferably a heteroatom such as oxygen, sulfur, or nitrogen groupings in linear, branched, or cyclic structural formats; and Z′ may a hydrogen atom, a halogen atom, a hydroxyl group, or any other organic groups or groupings which optionally include a heteroatom such as oxygen, sulfur, or nitrogen groupings in linear, branched, or cyclic structural formats.

Colon cancer cells in a sample are screened by analyzing the amount of expression of at least 2 or more genes or products thereof selected from the group of genes listed in Tables 1 and 30. As compared to conventional method, patients having colon cancer can be detected with higher accuracy. Colon cancer cells in stool are also screened by analyzing expression of genes selected from the group of genes listed in Table 37.

Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.

The invention provides methods, compositions and kits for inducing and/or enhancing an immune response in a subject. The invention in some aspects includes polypeptide and nucleic acid molecules that induce and/or enhance an immune response. In some aspects of the invention, the polypeptide and/or nucleic acid molecules of the invention are useful to induce and/or enhance an immune response in a subject who has or is suspected of having cancer.

The invention relates to a maackia amurensis total flavone extract as well as a preparation method and an application thereof. The maackia amurensis total flavone extract is prepared through the method which comprises the following steps: extracting the heartwood, velamen, bark, twig bark, leaves, stalks, flowers, fruits and seeds of maackia amurensis by utilizing an extraction solvent; filtering and concentrating the extracting solution; passing the concentrated solution through the macroporous adsorption resin, and eluting by utilizing methanol or ethanol water of different concentrations; and collecting and concentrating the eluant until the solution is dry, so that the maackia amurensis total flavone extract is obtained. The maackia amurensis total flavone extract which is obtained through the method contains the total flavone content of 15%- 90%, tectoridin of 1-15% and SaikoisoflavonosideA of 6-57%. The maackia amurensis total flavone extract has an estrogen effect, can be used for preparing estrogen drugs or health-care food and is used for preventing or treating breast cancer, prostate cancer, colon cancer, osteoporosis and climacteric syndrome.

The invention provides a method for prognosis judgment of colon cancer. The method comprises the step of detecting the amino acid sequence of a polypeptide, wherein the amino acid sequence is the sequence shown in SEQ NO.1 or a sequence with 99% of display content identical with the display content of the sequence shown in SEQ NO.1. A novel marker, namely HOXB-AS3 polypeptide, for prognosis evaluation and judgment of colon cancer is also provided. Clinical study proves that low expression or expression failure of the HOXB-AS3 polypeptide in colon cancer tissue is positively related to poor prognosis of colon cancer patients, and patients with low HOXB-AS3 polypeptide level in colon cancer tissue have higher death rate and shorter lifetime. Therefore, by using the HOXB-AS3 polypeptide as the biomarker, the positive coincidence rate is effectively increased when the kit is clinically applied to prognosis judgment of colon cancer. Furthermore, by detecting the level of the HOXB-AS3 polypeptide in a biological sample tissue slice, generation, malignancy grade and metastatic potential of colon cancer can be judged easily.

Methods for treating, preventing or delaying onset of polyp formation and subsequent colon cancer are disclosed. The methods involve administration of a complement inhibitor to inhibit C5a receptor signaling in the tumorigenic or pre-tumorigenic tissue.

The invention relates to a traditional Chinese medicinal composition for treating colon cancer hepatic metastases, which consists of the following raw material medicaments by weight: 3 to 9 grams of spreading hedyotis herb, 1,020 grams of golden thread, 20 to 40 grams of barbed skullcap herb, 20 to 40 grams of medlar, 5 to 20 grams of lightyellow sophora root, 5 to 20 grams of divaricate saposhnikovia root, 5 to 20 grams of bupleurum, 20 to 40 grams of swordlike atractylodes rhizome, 5 to 20 grams of large-headed atractylodes rhizome, 5 to 20 grams of dahurian patrinia herb, 20 to 40 grams of Indian iphigenia bulb, 20 to 40 grams of south dodder seed, 5 to 20 grams of black nightshade herb, 5 to 20 grams of ash bark, 20 to 40 grams of sargentodoxa stem, 20 to 40 grams of glossy privet fruit and 5 to 20 grams of amur corktree bark. The raw material medicaments are heated for extraction or diacolation in water or 30 to 90 percent ethanol, the material medicaments having been heated for the extraction or diacolation are purified to obtain extract, and then the extract is prepared into various preparations.

The invention discloses a 8-dihalomethyl berberine-type quaternary ammonium salt compound as shown in formulas I and II and a synthesis method and application to medicine preparation thereof. The 8-dihalomethyl berberine-type compound shows more pronounced hydrophilicity in the absence of a conventional hydrophilic group compared with a substrate; the 8-dihalomethyl berberine-type compound has significant antimicrobial activity, anti-inflammatory activity, anti-ulcerative colitis activity and anti-tumor activity; and clear and significant regulatory effects are shown in tumorigenesis related target molecules in tumor cells of colon cancer, liver cancer, lung cancer, breast cancer, osteosarcoma and glioma, and the significant anti-tumor activity is achieved. The 8-dihalomethyl berberine-type quaternary ammonium salt compound has higher pharmacological action intensity than control drugs, has the characteristic of no toxicity or low toxicity, and can be used for preparing medicine for preventing, alleviating and/or treating microbial infection, inflammation, the ulcerative colitis and the tumors. (Please see the specification for the formulas)

Compositions for the diagnosis and therapy of prostate and colon cancer, derived from or based on a novel prostate-specific, androgen-regulated, cell surface serine protease termed 20P1F12/TMPRSS2 are described. A full length cDNA comprising the entire coding sequence of the 20P1F12/TMPRSS2 gene (also designated 20P1F12-GTC1 herein) is provided (FIG. 1). Among the compositions provides are antibodies that bind to 20P1F12/TMPRSS2 proteins and polypeptide fragments thereof, including antibodies labeled with a detectable marker or toxin or therapeutic composition. Several monoclonal antibodies specifically reactive with 20P1F12/TMPRSS2 are also described herein.

The invention provides a human primary colon cancer cell separation and culture method. The method comprises the following steps of (1) cutting a fresh colon cancer tissue under an aseptic condition,sealing at 4 DEG C and then carrying back to a lab; (2) disinfecting a tissue processing device; (3) using a pair of operating scissors for separating the colon cancer tissue, placing the tissue intoa precooled sterile PBS liquid containing double antibodies, and washing multiple times to remove blood vessels, fat and necrotic tissues; (4) cutting up the tissues, and using preheated pancreatin and IV type collagenase for digesting respectively; (5) terminating digestion, centrifuging, and removing a supernatant; (6) using trypan-blue for dyeing a cell filter liquor to detect cell activity; (7) after carrying out cell counting, inoculating into a coated culture flask; (8) culturing at 37 DEG C in an environment with 5 percent of CO2; (9) purifying the cells; (10) subculturing the tissues;(11) observing cell morphology; (12) determining cell survival rate; (13) carrying out immunological identification. The invention provides the human primary colon cancer cell separation and culture method which is simple to operate, the number of the obtained cells is large, the survival rate is high, the method is the ideal human primary colon cancer cell primary separation and culture method, and a reliable cell resource is provided for experiments.

The invention provides a traditional Chinese medicine fermented beverage having efficacy of resisting tumors and a preparation method of the traditional Chinese medicine fermented beverage. The beverage consists of effective components of a Chinese wolfberry fruit and honeysuckle flower co-extract, a sugar solution, lactic acid bacteria, microzyme and acetic acid bacteria, wherein 300mL of the sugar solution, 1*10<3>-1*10<13>CFU of the lactic acid bacteria, 1*10<3>-1*10<13>CFU of microzyme and 1*10<3>-1*10<13>CFU of the acetic acid bacteria are added for every 500mL of the Chinese wolfberry fruit and honeysuckle flower co-extract. The lactic acid bacteria, the microzyme and the acetic acid bacteria are added to a mixed solution of the Chinese wolfberry fruit and honeysuckle flower co-extract and the sugar solution so that the traditional Chinese medicine fermented beverage is prepared. In vitro tests prove that the in vitro 72h suppression ratio of the beverage for HT29 (human colon cancer cell strains), S180 (mouse ascitic type sarcoma cell strains) and HpG2 (human liver cancer cell strains) is notable.

It is intended to provide a non-invasive and convenient method of detecting a tumor marker for diagnosing colon cancer which is superior in sensitivity and specificity to the existing fecal occult blood test. More specifically speaking, a method of detecting a tumor marker for diagnosing colon cancer which comprises collecting biological sample which is immediately frozen using liquid nitrogen in some cases, homogenizing the sample in the presence of an inhibitor of an RNA digesting enzyme to give a suspension, extracting RNA from the obtained suspension, subjecting the extracted RNA to reverse transcription to give cDNA, amplifying the obtained cDNA and then detecting the thus amplified cDNA. This method is characterized by involving no procedure of separating cell components from the biological sample.